



Community Acquired Pneumonia – Pediatric

Ages 3 month to 18 years

Clinical Practice Guideline

MedStar Health

Antibiotic Stewardship

“These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care of their patients. They are not a substitute for individual judgment brought to each clinical situation by the patient’s primary care provider in collaboration with the patient. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but should be used with the clear understanding that continued research may result in new knowledge and recommendations.”

These guidelines are intended to assist clinicians in treating community acquired pneumonia in otherwise healthy infants and children older than 3 months of age. These guidelines do not pertain to infants ≤ 3 months of age, immunocompromised children, children with chronic lung disease (ex: cystic fibrosis) or ventilator dependent children.

I. INITIAL PRESENTATION

- Fever (temperature ≥ 38.0 C or 100.4 F)
- Cough
- Abnormal lung sounds (rhonchi, , rales (crackles), wheezing)
- Variable degrees of respiratory distress (tachypnea, dyspnea, retractions, grunting, nasal flaring, apnea, altered mental status)

II. RISK FACTORS

A. General Risk Factors

- Age < 5 years
- Male
- Prematurity
- Malnutrition
- Exposure to tobacco smoke
- Childcare attendance
- Low socioeconomic status

III. SELECTION OF CARE SETTING

A. Conditions that favor **Outpatient management**:

- Absence of respiratory distress
- Sustained SpO₂ $\geq 90\%$
- Adequate outpatient caregiver support and ability to be compliant with outpatient therapy

B. Conditions that favor Inpatient management:

- Respiratory distress (tachypnea, dyspnea, retractions, grunting, nasal flaring, apnea, altered mental status)
- Sustained SpO₂ < 90%
- < 3 months of age with suspected bacterial pneumonia
- Suspected pathogen with increased virulence (ex: MRSA)
- Poor outpatient support with concerns about the ability to be compliant with outpatient therapy
- Failed outpatient therapy of presumed bacterial pneumonia with appropriate antibiotics for > 3 days.

IV. SPECIFIC PATHOGENS

A. Viruses

- Approximately 80% of CAP in children < 2 years of age is caused by a virus.
- The incidence of a viral etiology decreases with age. Viruses are responsible for CAP in children > 5 years of age in only 1/3 of cases.
- Common viruses:
 - *Respiratory syncytial virus* (found in up to 40% of children <2 years of age)
 - *Influenza A, B*
 - *Parainfluenza viruses 1, 2 and 3*
 - *Rhinovirus*
 - *Human metapneumovirus*
 - *Human bocavirus*
 - *Coronavirus*
 - *Adenovirus*

B. Atypical bacteria

- *Mycoplasma pneumoniae*
 - More common in older children and adolescents.
 - Course is classically slowly progressive and is associated with malaise, cough and no fever. (Also called Walking Pneumonia)
- *Chlamydia Trachomatis* and *Chlamydia Pneumoniae*
 - More often found in infants < 3 months age.
 - Transmitted vertically from the mother.
 - May be preceded by Chlamydial conjunctivitis in the neonatal period.

C. Bacteria (In order of prevalence)

- *Streptococcus pneumoniae* (most common)
- *Haemophilus influenzae, Non-typable*
- *Moraxella catarrhalis*
- *Staphylococcus aureus, including MRSA*

V. DIAGNOSTIC TESTING ROUTINELY RECOMMENDED

- **Pulse oximetry** should be performed in all children with pneumonia and suspected hypoxemia. The presence of hypoxemia should guide decisions regarding site of care and further diagnostic testing.
- **Rapid testing for influenza** is recommended when seasonally appropriate and available. A positive test would guide appropriate antiviral therapy. Additionally, antibacterial therapy is not recommended for children with a positive influenza test unless there is compelling evidence that there is a bacterial co-infection.

NOT ROUTINELY RECOMMENDED

- **Chest x-ray** is not necessary to confirm CAP in patients in the outpatient setting. Chest x-ray is a consideration for patients with a non-specific exam but persistent clinical symptoms consistent with pneumonia.
- **Blood cultures** are not routinely recommended for non-toxic, fully immunized children.
- **Acute phase reactants (ESR, CRP, procalcitonin)** should not routinely be obtained.
- ***Mycoplasma and Chlamydia* testing for pneumonia** is not routinely recommended.
- **Complete blood cell count** is not routinely recommended. However, it may provide useful information in patients with an unclear diagnosis or with concern for increasing systemic infection.
- **Antibacterial therapy is not necessary** for viral pneumonia. However, be alert for clinical symptoms consistent with a bacterial super-infection after a viral illness. **Staphylococcal (MRSA) pneumonia is a frequent complication after influenza infection.**

VI. DRUG THERAPY

- **Amoxicillin should be used as first-line therapy** for previously healthy, appropriately immunized infants and preschool children with mild to moderate CAP suspected to be of bacterial origin. Amoxicillin provides appropriate coverage for *Streptococcus pneumoniae*, the most prominent invasive bacterial pathogen.

Table 1 lists preferred agents and alternative agents. See section VII for children allergic to amoxicillin.

- **Macrolide antibiotics** should be prescribed for treatment of children (primarily school-aged children and adolescents) with findings compatible with **CAP caused by atypical pathogens. Table 1 lists preferred and alternative agents for atypical pathogens.**
- **Influenza antiviral therapy should be administered as soon as possible to children with moderate to severe CAP consistent with influenza virus infection** during widespread local circulation of influenza viruses. Antiviral treatment provides maximal benefit when started early (< 48-72 hours). Treatment with antiviral therapy should not be delayed if influenza is suspected but influenza testing is not available. Negative influenza diagnostic tests, especially rapid antigen tests, do not conclusively exclude influenza disease.

Table 1.**Empiric Therapy for Outpatient Pediatric Community-Acquired Pneumonia (CAP)**

Presumed bacterial pneumonia	Presumed atypical pneumonia	Presumed influenza pneumonia
<p>Amoxicillin, oral 90 mg/kg/day in 2 doses for 10 days max 4 g/day</p> <p>Alternative: amoxicillin- clavulanate Dose amoxicillin component, standard 45mg/kg/day or high dose (ES with lower clavulanate) 90 mg/kg/day Divide in 2 doses for 10 days. Max of 4 g/day</p>	<p>Azithromycin oral 10 mg/kg (max 500mg) on day 1, followed by 5 mg/kg/day (max 250 mg) once daily on days 2– 5;</p> <p>Alternatives: oral clarithromycin (15 mg/kg/day in 2 doses for 7-14 days) or oral erythromycin (40 mg/kg/day in 4 doses for 7-14 days)</p>	<p>Oseltamivir</p> <p>≥24 months old: ~4 mg/kg/day in 2 doses, for a 5-day treatment</p> <p>≤15 kg: 60 mg/day; >15 to 23 kg: 90 mg/day; >23 to 40 kg: 120 mg/day; >40 kg: 150 mg/day (divided into 2 doses for each group)</p> <p>9–23 months old: 7 mg/kg/day in 2 doses; 0–8 months old: 6 mg/kg/day in 2 doses; premature infants: 2 mg/kg/day in 2 doses</p>

VII. AMOXICILLIN OR PENICILLIN ALLERGY:

For children with a history of non-anaphylactic allergic reactions to amoxicillin, treatment is not well defined and should be individualized.

- Options include:
- 1) a trial of amoxicillin under medical observation;
 - 2) 2nd or 3rd generation cephalosporin, or
 - 3) clindamycin.

Anaphylactic or life threatening reactions to penicillin should be treated with clindamycin.

Azithromycin is only partly effective for pneumonia. It has limited action against resistant Strep Pneumoniae which causes 25% or more cases of pneumonia in children.

VIII. DURATION OF TREATMENT

- A. Treatment of 10 days is recommended in CAP in pediatric patients. Treatment with shorter courses of 5-7 days has been best studied and shown to be equally effective in adults. Short duration of antibiotics is not currently recommended in pediatric patients.
- B. Complicated CAP and Infections caused by certain pathogens, notably CA-MRSA, may require longer treatment than those caused by *S. pneumoniae*.
- C. Azithromycin is dosed for 5 days due to different tissue-site pharmacokinetics.

IX. MINIMIZING ANTIMICROBIAL RESISTANCE

- A. Antibiotic exposure selects for antibiotic resistance; therefore, **limiting exposure to any antibiotic**, whenever possible, is preferred.
- B. **Limiting the spectrum of activity of antimicrobials** to that specifically required to treat the identified pathogen is preferred.
- C. **Using the proper dosage of antimicrobial** to be able to achieve a minimal effective concentration at the site of infection is important to decrease the development of resistance.
- D. **Treatment for the shortest effective duration** will minimize exposure of both pathogens and normal microbiota to antimicrobials, and minimize antimicrobial resistance.

X. RESPONSE TO TREATMENT

- A. Children receiving adequate therapy should demonstrate clinical signs of improvement within 48–72 hours. If repeat laboratory testing is done, ideally there will be improvement from baseline labs. However, initial and repeat lab testing is not necessary, clinical improvement should be the determination of adequate therapy.
- B. For children who show no improvement in fever or clinical symptoms within 48–72 hours after diagnosis and initiation of antimicrobial therapy, consideration of further investigation or adjustment of antibiotic coverage should be performed.
- C. Clinical deterioration at any timing should receive a higher level of care.

XI. PATIENT EDUCATION

Please review the information below with your patients.

- A.** Pneumonia is an infection of the lungs. Bacterial pneumonia is treated with antibiotics. Influenza may be treated with antiviral drugs such as Oseltamivir, if diagnosed early. Viral pneumonia does not get better with antibiotics.
- B.** Catching illnesses such as pneumonia, upper respiratory infections (colds) other respiratory infections can be decreased by following good hygiene practices. Wash your hands regularly and disinfect frequently touched surfaces.
- C.** If you smoke and/or vape, stop.
- D.** Avoid exposure to cigarette and/or vape smoke.
- E.** Make sure the child and all family members are up to date on the vaccines including the flu shot.
- These vaccines include:
 - Pneumococcal (Pneumovax)
 - *HIB (Haemophilus influenzae b)*
 - Pertussis (whooping cough in DTaP or Tdap)
 - Varicella (chicken pox)
 - Measles (MMR)
 - Influenza (flu)
- F.** Call your physician and get seen, if your child shows any of the following warning signs that the pneumonia is getting worse.
- Fever lasting more than 3 days after starting antibiotics
 - Increasing breathing difficulties
 - Signs of dehydration, not drinking, repeated vomiting and decreased urination.
 - Evidence of an infection elsewhere in the body: red swollen joints, bone pain, severe headache, stiff neck, vomiting, or other new signs or symptoms.
 - Skin around mouth or fingers look blue or dusky.
- G.** Parents should follow these home care guidelines
- Rest.
 - Increase fluid intake.
 - No cough suppressants (such as codeine or dextromethorphan [DM]).
Coughing is necessary to clear the excessive secretions caused by the infection and open the airways.
 - Use over the counter drugs such as acetaminophen or ibuprofen to relieve fever or pain.

References:

1. Bradley, J. S., Byington, C. L., Shah, S. S., Alverson, B., Carter, E. R., Harrison, C., et al. (2011). The Management of Community-Acquired Pneumonia in Infants and Children Older than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clinical Infectious Diseases*, 52.
2. Esposito, S., Cohen, R., Domingo, J., Pecurariu, O., Greenberg, D., Heininger, U., et al. (2012). Do We Know When, What and for How Long to Treat? Antibiotic Therapy for Pediatric Community-Acquired Pneumonia. *The Pediatric Infectious Disease Journal*, e78-e85.
3. Harris, M., Clark, J., Coote, N., Fletcher, P., Harnden, A., McKean, M., et al. (2011). British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Children: Update 2011. *Thorax*, ii1-ii23.
4. Honkinen, M., Lahti, E., Osterback, R., Ruuskanen, O., & Waris, M. (2012). Viruses and Bacteria in Sputum Samples of Children with Community- Acquired Pneumonia. *Clinical Microbiology and Infection*, 200-307.
5. Huang, C.-Y., Chang, L., Liu, C.-C., Huang, Y.-C., Chang, L.-Y., Huang, Y.-C., et al. (2013). Risk Factors for Progressive Community-Acquired Pneumonia in Hospitalized Children: A Prospective Study. *Journal of Microbiology, Immunology and Infection*, 36-42.
6. McIntosh, K. (2002). Community-Acquired Pneumonia in Children. *New England Journal of Medicine*, 429-437.
7. Stuckey-Schrock, K., Hayes, B. L., & George, C. M. (2012). Community-Acquired Pneumonia in Children. *American Family Physician*, 661-667.
8. World Health Organization. (2014, November). *World Health Organization*. Retrieved July 8, 2015, from Fact Sheet: Pneumonia: <http://www.who.int/mediacentre/factsheets/fs331/en/>
9. Wubbel, L., Muniz, L., Ahmed, A., Trujillo, M., Carubelli, C., McCoig, C., et al. (1999). Etiology and treatment of community-acquired pneumonia in ambulatory children. *The Pediatric Infectious Disease Journal*, 98-104.

<p><u>Initial Approval Date and Reviews:</u> Effective 10/1/2015 by Pediatric Ambulatory Workgroup October 2017</p>	<p><u>Most Recent Revision and Approval Date:</u> <u>October 2019</u></p>	<p><u>Next Scheduled Review Date:</u> October 2021 Pediatric Ambulatory Workgroup Condition: Community Acquired Pneumonia - Pediatric</p>
--	---	---